Alkermes plc.

Alkermes plc is an Ireland-based, fully integrated global biopharmaceutical company focused on developing and commercializing innovative medicines in neuroscience. It specializes in treatments for serious mental illnesses, addiction, schizophrenia, bipolar I disorder, alcohol and opioid dependence, and sleep disorders such as narcolepsy and idiopathic hypersomnia. Key marketed products include Vivitrol for alcohol and opioid dependence, Aristada and Aristada Initio as long-acting injectables for schizophrenia, Lybalvi combining olanzapine and samidorphan for schizophrenia and bipolar I disorder, and manufacturing and royalty agreements for products like Invega long-acting formulations and Vumerity for multiple sclerosis. Alkermes employs proprietary technologies such as NanoCrystal, extended-release microsphere, and LinkeRx platforms to create competitively advantaged therapies. Its investigational pipeline features alixorexton, an oral orexin 2 receptor agonist advancing in phase 2 and 3 studies for narcolepsy types 1 and 2 and idiopathic hypersomnia, alongside other candidates like once-nightly sodium oxybate formulations. With R&D in Waltham, Massachusetts, and manufacturing in Wilmington, North Carolina, Alkermes plc plays a vital role in addressing unmet needs in psychiatric and neurological disorders through patient-inspired science and specialized commercial infrastructure. Founded in 1987 and headquartered in Dublin, Ireland, it serves healthcare and life sciences sectors worldwide.